Answers are grounded in this paper and cite their sources.
Real-world study assesses antiviral effectiveness and lipid changes in treatment-naïve individuals using a DOR-based regimen, suggesting favorable outcomes.
The newly approved oral anti-HIV doravirine (DOR)-based regimen in China in treatment-naïve people living with HIV (PLWH) remains inadequately characterized in China, particularly regarding antiviral efficacy and lipid profile changes. This study aimed to assess 48-week antiviral effectiveness and lipid changes associated with a DOR-based regimen in treatment-naïve PLWH compared with other regimens. A real-world retrospective study was conducted involving treatment-naïve PLWH who initiated DOR/TDF/3TC, EFV/TDF/3TC, DTG/TDF/3TC, or BIC/TAF/FTC. At week 48, 96.22% of participants receiving DOR/TDF/3TC achieved viral suppression, accompanied by significant increases in CD4 + T-cell counts. No treatment-related adverse events were reported in the DOR group. There were no statistically significant differences in virologic suppression or CD4 + T-cell increases among the four regimens (all P > 0.05). Regarding lipid parameters, DOR/TDF/3TC was associated with significant reductions in total cholesterol (TC) and triglycerides (TG) at weeks 36 and 48 (all P < 0.05), whereas BIC/TAF/FTC showed significant increases at all four post-treatment timepoints in TG, TC, and low-density lipoprotein cholesterol (LDL-C) (all P < 0.05). Between-group comparisons showed lower levels with DOR group versus BIC group in TG, TC, and LDL-C at week 48 ( P < 0.05). DOR showed lower levels in TC than EFV across the four time points (all P < 0.05). DOR/TDF/3TC demonstrated antiviral effectiveness comparable to DTG/TDF/3TC and BIC/TAF/FTC, with a favorable tolerability profile at week 48. Additionally, DOR/TDF/3TC was associated with more favorable lipid changes.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: